CC
MRNS

Caxton Corporation’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Caxton Corporation’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,361
Closed -$176K – 31
2018
Q4 		$176K Buy
15,361
+10,316
+204% +$209K 0.21% 23
2018
Q3 		$202K Buy
5,045
+1,769
+54% +$50.3K 0.19% 27
2018
Q2 		$93K Sell
3,276
-3,431
-51% -$76.1K 0.03% 24
2018
Q1 		$102K Buy
6,707
+2,046
+44% +$48.7K 0.11% 21
2017
Q4 		$152K Buy
4,661
+611
+15% +$16.5K 0.18% 19
2017
Q3 		$95K Buy
+4,050
New +$45.4K 0.1% 16

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Caxton Corporation's MRNS Position: Q1 2019 in Review

Caxton Corporation sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2019, closing a stake of 15,361 shares — an estimated $176K sold.

Caxton Corporation first reported a position in MRNS in Q3 2017 and held it in 6 quarters. The position peaked at $202K in Q3 2018. 81 funds tracked by Wall St. Rank hold MRNS as of Q1 2019.

  • Caxton Corporation reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • Caxton Corporation sold 15,361 Marinus Pharmaceuticals, Inc shares in Q1 2019, an estimated $176K.
  • Caxton Corporation first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 6 quarters.
  • Caxton Corporation's Marinus Pharmaceuticals, Inc position peaked at $202K in Q3 2018.
  • 81 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2019.

Based on Caxton Corporation's 13F filing for Q1 2019, filed 14 May 2019.